Settlement the best way forward in Sanofi-Aventis and Sun's Eloxatin spat?
This article was originally published in Scrip
Executive Summary
A new settlement option is being projected by some observers as the ideal way forward in the case concerning Sun Pharmaceutical Industries' generic challenge to Sanofi-Aventis' colon cancer drug Eloxatin (oxaliplatin injection) in the US.